A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
- Conditions
- ipoprotein DisorderTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2022-501426-38-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 255
Participants must be at least 40 years old and have Lp(a) level =175 nmol/L at screening, Participants if on lipid-lowering drugs or hormone therapy need to be on stable dose for at least 4 weeks prior to screening, A body mass index within the range 18.5 to 40 kilogram/square meter, Males who agree to use highly effective contraception methods or women not of childbearing age
Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that in the opinion of the investigator, would affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data., Had major surgery within 3 months of day 1, Had coronary, carotid, or peripheral arteria revascularization, stroke, heart attack or chest pain within 3 months of day 1, Have uncontrolled diabetes, Have uncontrolled high blood pressure, Women of childbearing potential
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method